BlessUp Peptide Library · Longevity & Aging

The longevity class, decoded

Epitalon, FOXO4-DRI, fisetin, spermidine, rapamycin, NAD+ boosters. Six ways at aging, aimed at four different failure modes.

The mechanisms map onto real aging biology. The human proof is thinner than the hope.

4
hallmarks of aging this class targets: telomeres, senescence, autophagy, NAD+
~50%
the drop in your NAD+ levels between roughly age 40 and 60
0
of them has a proven human lifespan or healthspan outcome. Every result is short-term

NAD+ decline: Covarrubias 2021, Nat Rev Mol Cell Biol. Human results in this class are biomarker-level and short-term. Full citations at the end.

You have seen them sold as the anti-aging shelf: Epitalon for your telomeres, FOXO4-DRI and fisetin to clear old cells, spermidine and rapamycin for cellular cleanup, NMN and NR to refill NAD+. Six very different compounds, all wearing the same "live longer" label.

Here is the honest version. Aging is not one thing, it is a set of distinct failure modes that scientists call the hallmarks of aging, and each of these compounds is aimed at a different one. They barely compete, because they target different problems. That part is genuinely interesting, and much of the biology is real. The catch is the evidence: nearly every human result in this entire class is a short-term change in a biomarker, a lab value, not a proven change in how long or how well anyone actually lives. So the useful thing we can do is line each compound up against the hallmark it targets and the proof it actually has, honestly. And we lead with the part nobody wants to hear: the free things you already know about outrank all of them. We do honest, not hype.

Read this first

This is education, not medical advice, and it does not replace your own clinician. Of this class, only rapamycin is an approved drug (used off-label here); the NAD+ precursors are supplements; Epitalon and FOXO4-DRI are research compounds, and FOXO4-DRI has no human trials at all. None is a proven longevity treatment in humans. Any dose named here is an example for discussion, never a prescription.

90-second self-check

Are you cleared to explore this class, and which lever fits?

This flags the safety stops, and if you are clear, points toward the hallmark that matches your goal, and away from the compounds that are not ready. It is education, not a diagnosis or a recommendation to use anything.

Longevity class readiness and fit

Answer honestly. Nothing is stored, and no one sees it but you.

First, the hard stops. Do any of these apply to you? (tap all that are true)

Which hallmark of aging are you most interested in acting on?

Any of these in your picture? (tap all that apply)

Is the real foundation in place? (tap all that apply)

This reflection is education only, not a diagnosis or a recommendation to use any compound. Talk to a licensed provider about your own history and goals.

The basics

Four failure modes, six tools

Aging is not a single switch. Researchers describe it as a set of hallmarks, distinct ways cells and tissues break down over time. Four of them are what this class is aimed at, and each compound targets a different one:

  • Telomere attrition. The protective caps on the ends of your chromosomes shorten every time a cell divides. Epitalon is studied for helping rebuild them.
  • Cellular senescence. Damaged cells stop dividing but refuse to die, becoming inflammatory "zombie" cells that poison their neighbors. FOXO4-DRI and fisetin are studied for clearing them (senolytics).
  • Loss of autophagy. The cell's recycling crew, which clears out damaged parts, slows with age. Spermidine and rapamycin are studied for switching it back on.
  • NAD+ decline. NAD+, a coenzyme that runs your energy and repair machinery, falls by roughly half between age 40 and 60. NMN, NR, and injectable NAD+ are studied for topping it back up.
CompoundHallmark targetedMechanism (in brief)Evidence levelRoute
EpitalonTelomere attritionTelomerase activation; pineal rhythmMostly-Russian; no human trialSubQ, short courses
FOXO4-DRICellular senescenceFrees p53 to kill senescent cellsPreclinical only; no human dataSubQ (experimental)
FisetinCellular senescenceSenolytic flavonoid; cuts survival signalsHuman-early (trials ongoing)Oral (pulse dosing)
SpermidineAutophagySwitches on the recycling programHuman-early + strong observationalOral / dietary daily
RapamycinAutophagy / mTORInhibits mTOR, the growth brakeAnimal-strong; human-emergingOral weekly (off-label)
NMN / NR / NAD+NAD+ declineRefill the NAD+ coenzymeHuman-early (biomarkers)Oral daily; NAD+ by injection

The honest half-truth you will hear

"These are proven to slow aging." Not in humans, not yet. The mechanisms are real and map onto genuine aging biology, and rapamycin extends lifespan in animals across many species. But in people, nearly every result is a short-term biomarker change (NAD+ went up, a senescence marker went down, an immune response improved), not a demonstrated increase in how long or how well anyone lives. Promising biology is not the same as a proven human outcome.

The part the marketing flattens

The evidence gradient is steep

These get sold on the same shelf as if the proof were equal. It is not, and the range is large. Here is an honest read of how much real evidence sits behind each. Longer bars mean deeper, more rigorous evidence, weighted toward human data, not "works better."

Depth of evidence, by compound

Rapamycin leads on animal lifespan data; the middle is real-but-early human biomarker data; the bottom is Russian-only or preclinical.

Rapamycin
Deep animal lifespan data
NMN / NR / NAD+
Human RCTs, but on biomarkers
Spermidine
Human-early + observational
Fisetin
Animal + early human trials
Epitalon
Mostly-Russian; no human trial
FOXO4-DRI
Preclinical only; no human data

Synthesized from Harrison 2009 & Mannick 2014 (rapamycin), Yoshino 2021 (NMN), Eisenberg 2016 (spermidine), Yousefzadeh 2018 (fisetin), Baar 2017 (FOXO4-DRI). Epitalon: no human administration trial exists. Full citations below.

Read the shape honestly. Even rapamycin, the leader, has its lifespan data in animals, not a completed human longevity trial. The middle three have real human RCTs, but on biomarkers over weeks or months. Epitalon rests on Russian-tradition studies with no human administration trial, and FOXO4-DRI has been tested only in cells and mice. Newer and more exciting does not mean better proven.

Under the hood

Four different repairs

TELOMERES

Rebuild the caps

Every cell division shortens the protective caps on your chromosome ends. Epitalon is studied for reactivating telomerase to add length back. The honest catch: telomere lengthening is also how cancer cells stay immortal, so longer is not automatically safer.

SENESCENCE

Clear the zombie cells

Old damaged cells that will not divide or die leak inflammation into surrounding tissue. Senolytics target them: FOXO4-DRI frees p53 to trigger their self-destruct; fisetin shuts off the survival signals they lean on. Both spare healthy cells.

AUTOPHAGY

Restart the recycling

Autophagy clears damaged proteins and worn-out cell parts, and it slows with age. Spermidine switches the program back on directly; rapamycin does it by releasing mTOR, the nutrient-sensing brake. Fasting and exercise hit the same switch for free.

NAD+

Refill the coenzyme

NAD+ powers energy metabolism, DNA repair, and the sirtuin "longevity" enzymes, and it falls by about half by age 60. NMN and NR are precursors that refill it; injectable NAD+ tops it up directly. All reliably raise the level.

The members, with honest pros and cons

Each one, against its hallmark

They barely compete, because they target different failure modes. Tags show the hallmark: telomeres, senescence, autophagy, or NAD+.

Epitalon

Telomeres

A Russian-developed pineal peptide studied for reactivating telomerase and rebuilding the caps on your chromosomes.

Pros
  • One of very few compounds with any telomerase-activation and rodent-lifespan data
  • Also studied for normalizing melatonin and circadian rhythm
  • Very well tolerated in the limited data, dosed as short courses
Cons
  • The human evidence is mostly Russian-tradition; no peer-reviewed human administration trial exists
  • Telomere lengthening is also how cancer cells stay immortal, a real directionality watch-out
  • Effects are measured on labs, not felt, and are unproven for any human outcome

Honest read: intriguing and unproven in humans. A research compound, not an established therapy. Dosed in short SubQ courses, pinned alone.

FOXO4-DRI

Senescence · wait for data

An elegantly designed senolytic peptide that frees p53 inside senescent cells to trigger their self-destruct. The most mechanistically beautiful, and the least proven.

Pros
  • A precise, purpose-built senolytic: selective apoptosis of senescent cells, sparing healthy ones
  • Restored fitness, fur, and kidney function in aged mice
  • A genuinely interesting target for continued research
Cons
  • No human trials at all: no human dosing, safety window, or efficacy data
  • The newest compound with the least safety data of anything in the class
  • All human dosing is extrapolated from mice, which is not a safety basis

Honest read: a research story, not a run-it-well compound. The sensible move is to follow the science and wait for human data, not to be the experiment.

Fisetin

Senescence

A food-derived flavonoid senolytic (from strawberries and apples) with genuine early human trials. The lower-risk way at clearing senescent cells.

Pros
  • The most potent of ten flavonoids screened, and it extended mouse lifespan roughly 10%
  • A natural compound with a good safety record, dosed as a short monthly pulse
  • Being tested in real human clinical trials
Cons
  • No large completed human trial has yet confirmed the senolytic effect in people
  • Poor oral absorption (roughly 1 to 5%), so it is unclear how much reaches tissue
  • May interfere with chemotherapy and may add to blood-thinner effects

Honest read: a reasonable, low-risk early-adopter senolytic. Typically dosed high for 2 to 3 days a month (hit and run), with fat for absorption.

Spermidine

Autophagy

A natural polyamine (from wheat germ and aged cheese) that switches on autophagy. A caloric-restriction mimetic, and the best-evidenced supplement here.

Pros
  • A strong mechanism plus the standout human signal: higher dietary intake tracked with lower mortality in a 20-year population study
  • Two small trials suggested memory benefit
  • Very well tolerated, available from food and as a supplement
Cons
  • Most human data is observational or short, no long-term survival trial exists
  • Optimal dose and form are unproven, and gut bacteria metabolize some of it
  • The benefit is real but modest and slow, not dramatic

Honest read: the low-risk, food-based autophagy option with the best observational support. Dosed 1 to 2 mg daily, ongoing.

Rapamycin

Autophagy / mTOR

An approved immunosuppressant drug used off-label for longevity, and the compound with the deepest animal lifespan data of anything here.

Pros
  • The only drug shown to extend lifespan across many species, even started late in life (about 9 to 14% in mice)
  • A landmark human trial showed an mTOR inhibitor improved the elderly immune response to a vaccine by roughly 20%
  • A real, well-characterized drug with a defined mechanism
Cons
  • It is an immunosuppressant: mouth sores, raised lipids and glucose, impaired wound healing, and infection risk
  • Major drug interactions through the liver (CYP3A4), so dosing needs a knowledgeable provider
  • No completed human longevity trial; the low-dose weekly protocol is rationale plus animal data

Honest read: the most animal-proven and the most serious. Clinician-supervised and experimental only. Dosed weekly, off-label, with monitoring.

NMN, NR, and injectable NAD+

NAD+

The NAD+ toolkit: precursors (NMN, NR) and direct repletion (injectable NAD+) to refill the coenzyme that falls with age. The class's most reproducible effect.

Pros
  • The most reliably demonstrated result here: human trials consistently raise blood NAD+
  • NMN improved muscle insulin sensitivity in prediabetic women in a controlled trial
  • Generally very well tolerated, oral and convenient (NR has the longest human track record)
Cons
  • Raising NAD+ is a biomarker, not a proven outcome: human lifespan or healthspan benefit is unproven
  • Mouse lifespan effects were modest or absent, so human translation may be incremental
  • Injectable NAD+ stings and has limited data; NMN's regulatory status shifted in 2022

Honest read: a real, low-risk biomarker win, with an unproven bottom line. Dosed daily (NMN 250 to 500 mg, NR up to 1000 mg); pair NR with TMG. For the deeper hype-versus-evidence dive on NAD+ and NMN specifically, see the dedicated NAD and NMN guide.

The line that matters most

Raising a lab value is step one of about fifty

The single most important thing to understand about this class is the gap between a biomarker and an outcome. It is genuinely true that NAD+ boosters raise your NAD+, that senolytics reduce markers of senescence, that rapamycin engages mTOR. Those are real, measurable effects. But a compound doing its job in your bloodwork is not the same as you living longer or healthier, and for every compound on this page, that second step, the human outcome, has not been shown.

Two things to hold onto

First, FOXO4-DRI is the clearest case of mechanism running ahead of evidence: an elegant senolytic with zero human data. Treat it as research to watch, not a compound to run. Second, the whole class is an add-on, not a foundation. The interventions with the strongest human longevity evidence are not on this page, they are the free ones below.

The cautions that matter

The safety picture

Several of these are low-risk supplements, but a few lines are firm, and one member (rapamycin) is a serious drug.

1

Active or recent cancer

This cuts across the class and is nuanced. Telomere activation (Epitalon) and NAD+ both feed cell growth and proliferation; fisetin's senolytic action may interfere with chemotherapy that relies on senescence. Anyone with active or recent cancer, or in treatment, needs an oncologist in the loop before any of these.

2

Rapamycin: immune suppression, infection, and surgery

Rapamycin is a real immunosuppressant. It raises infection risk and impairs wound healing, so a weakened immune system, an active infection, or upcoming surgery are direct reasons to stop and involve a provider (and to pause it before any procedure).

3

Rapamycin: major drug interactions

Rapamycin is processed by the liver's CYP3A4 pathway, so many common medicines can send its levels up or down dangerously. If you take prescription medication, rapamycin is a provider-managed decision, not a self-dosed one.

4

Blood thinners and fisetin

Fisetin has a mild blood-thinning effect and may add to anticoagulants like warfarin. If you take a blood thinner, clear it first.

5

Research compounds with little or no human safety data

FOXO4-DRI has no human trials, and Epitalon has no human administration trial. Their doses are extrapolated, not validated, and pregnancy and breastfeeding are blanket cautions across the class. Treat both as experimental.

The one rule under all of it

Start with the lowest-risk members that fit your goal (the supplements), keep anything clinical (rapamycin above all) with a provider, be honest that Epitalon is Russian-data-only and FOXO4-DRI is preclinical, and build the foundation below first, because it does more than any of these.

Put it together

How to think about choosing, honestly

First question

Are you cleared, and is the base built?

  • No active or recent cancer; not pregnant or breastfeeding
  • No immune suppression, active infection, or imminent surgery (matters most for rapamycin)
  • Prescription meds and blood thinners cleared with a provider
  • Fasting, exercise, and sleep actually in place first (they outrank all of this)

Second question

Which hallmark, at what risk?

  • NAD+, lowest risk, real biomarker data: NR or NMN
  • Autophagy, low risk: spermidine (food-based) or fasting for free
  • Senescence, early human data: fisetin (monthly pulse)
  • Deepest animal proof, accept drug risk: rapamycin, clinician-led only
  • Telomeres or the FOXO4 senolytic: Epitalon and FOXO4-DRI are unproven, treat as research

The move most people skip

Do the free interventions first and give them real effort. Then, if you still want to, add the lowest-risk compound that fits one hallmark, and hold anything serious for a provider. Matching beats maxing, and the foundation beats the shelf.

The foundation that outranks the shelf

The free interventions win

This is the part the vault research keeps stressing, and it is worth saying plainly: the interventions with the strongest human longevity evidence are not compounds, they are habits. The peptides and precursors are the last five percent, not the first eighty.

Fasting and not overeating

Time-restricted eating and simply not overeating lower mTOR and raise autophagy through the exact same pathway that rapamycin and spermidine target, proven and free. If you are not already doing this, it is the higher-value starting point, not a drug.

Exercise

Exercise is the benchmark the best supplement in this class is measured against, the spermidine mortality signal was described as comparable in size to moderate exercise. It also restores your own NAD+ salvage capacity in muscle. It is the single most evidence-backed longevity intervention there is.

Sleep and circadian rhythm

Deep, regular sleep is the pineal and circadian health that Epitalon only claims to support, available directly and for free. Protect it first.

Muscle and metabolic health

Maintaining muscle mass, blood-sugar control, and cardiovascular health does more for how long and how well you live than anything on this page. The compounds sit on top of that, they do not replace it.

Cutting through the noise

The shelf, graded honestly

Solid

Fasting or time-restricted eating, exercise, and real sleep

The genuinely evidence-backed longevity foundation. This is what actually moves healthspan, and it is free. Boring, and it works.

Reasonable

Spermidine, NR or NMN, and fisetin, on top of the foundation

Lower-risk members with real (if early or biomarker-level) human data. Reasonable to add once the basics are handled, with modest expectations.

Unproven

Epitalon for telomeres, or high-dose NAD+ stacks for "reversal"

Intriguing but unproven in humans. Epitalon has no human trial; big NAD+ stacks raise a lab value without a proven outcome. Curiosity, not confidence.

Skip

FOXO4-DRI on the strength of the mouse data, or rapamycin without a provider

FOXO4-DRI has zero human data; rapamycin is a serious immunosuppressant with real interactions. Neither belongs in a self-directed protocol right now.

Turn this into action

Questions to ask yourself

Have I ruled out the hard stops: active or recent cancer, pregnancy, and immune suppression or upcoming surgery?

Am I actually fasting, exercising, and sleeping, since those outrank everything on this page?

Am I honest that I would be buying a biomarker change, not a proven longer or healthier life?

If I take prescription meds, have I checked interactions (especially for rapamycin)?

Am I choosing the lowest-risk member for one hallmark, not stacking six at once?

Bring these to your visit

Questions to ask your provider

Given my history and medications, is any of this reasonable, and which one?

If rapamycin, how would we dose and monitor it, and what interacts with it?

What baseline labs make sense (glucose, lipids, and others), and how often to recheck?

What symptoms should make me stop and call you?

Stop and get medical help

A few situations are not "go slower," they are "stop and be seen."

  • Signs of infection while on rapamycin: fever, spreading redness, feeling very unwell
  • A wound that will not heal, especially around a procedure
  • Any new lump or change you are worried could be cancer
  • Severe or persistent mouth sores, or a big change in blood sugar or lipids
  • Unusual bruising or bleeding if you take a blood thinner with fisetin
  • Any severe allergic reaction: swelling of the face or throat, trouble breathing

A little GI upset from a supplement settles. A fever on an immunosuppressant, a non-healing wound, or a new lump do not wait. When in doubt, be seen.

The BlessUp take

Match the tool to the hallmark, and the foundation to your life

The science here is real and genuinely exciting: aging is a set of distinct failure modes, and each of these compounds is aimed at one of them, telomeres, senescent cells, autophagy, NAD+. Rapamycin has the deepest animal lifespan data of anything in wide discussion. But the honest headline is the gap between a lab value and a life: in humans, this whole class has moved biomarkers, not proven outcomes, and the trendiest member, FOXO4-DRI, has no human data at all. So do not confuse a mechanism for a result. Start where the evidence is strongest, and it is not on the shelf, it is fasting, exercise, and sleep, which work through the same pathways for free. Then, if you want to, add the lowest-risk compound that fits one hallmark, keep anything serious with a provider, and treat the research compounds as science to watch. That is not the cautious move. It is the one that actually respects how aging works.

This is educational information only and not a recommendation to use, purchase, or dose any compound; it does not replace evaluation by your own licensed provider. None of these is an approved longevity treatment; rapamycin is an approved drug used off-label, the NAD+ precursors are supplements, and Epitalon and FOXO4-DRI are research compounds (FOXO4-DRI has no human trials). Human results in this class are short-term and biomarker-level, not proven lifespan or healthspan outcomes. Doses named are examples for discussion. Intended for adults 21 and over.

Learn it honest. Bless up.

The evidence

Sources

Retrieved from PubMed. Rapamycin's lifespan data is in animals; the human results (NMN, NR, mTOR-immune, fisetin, spermidine) are short-term and biomarker-level. Epitalon has no peer-reviewed human administration trial, and FOXO4-DRI has only preclinical (cell and mouse) data.

  1. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. doi:10.1038/nature08221 (the flagship animal lifespan result)
  2. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. doi:10.1126/scitranslmed.3009892 (human RCT; ~20% better vaccine response)
  3. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147. doi:10.1016/j.cell.2017.02.031 (the foundational FOXO4-DRI paper; preclinical)
  4. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. doi:10.1016/j.ebiom.2018.09.015
  5. Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016;22(12):1428-1438. doi:10.1038/nm.4222 (mouse lifespan + human dietary correlation)
  6. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985 (human NMN RCT)

Citations retrieved from PubMed. Every human result above is short-term and biomarker-level; none demonstrates extended human lifespan or healthspan. Epitalon rests on Russian-tradition research with no human administration trial; FOXO4-DRI has only cell and mouse data. This report is an honest educational map of the class, not a dosing sheet or a recommendation to use any compound.